While the potential benefits of CGT to patients seem clear, the high costs are hard for healthcare systems to carry. A single dose of a treatment can cost millions of dollars which makes access to those therapies very restricted. To be able to reach the full potential of cell and gene therapies in curing diseases, stakeholders need to focus on the ability to manufacture bioproducts concentrated in high quality and efficacious titers. However, viral manufacturing is not simple, with multiple complex challenges ranging from starting material generation, ensuring cellular production of high titers of viral vectors, to purification, where not all viral particles contain the intended genetic payload.

To define optimal conditions for a specific process, we support our customers with a free viral vector DoE (Design of Experiment) service, as part of our scientific support Compared to the, one-factor-at-a-time (OFAT) method, DoE is the most cost-efficient way to design experiments, increase productivity, save time, and tackle the toughest challenges in process development.